Global Zaleplon Market Analysis (2019 - 2030)
Global Zaleplon Market Analysis (2019 - 2030)
Source: pr-inside.com
📰 Hikma Pharms News
Hikma Pharms News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Hikma Pharms. Real-time updates on events, politics, business and more.
Global Zaleplon Market Analysis (2019 - 2030)
Global Zaleplon Market Analysis (2019 - 2030)
Source: pr-inside.com
Amarin Pharm., Inc. v. Hikma Pharms. USA Inc. | Robins Kaplan LLP
Case Name: Amarin Pharm., Inc. v. Hikma Pharms. USA Inc., No. 20-1630-RGA-JLH, 2022 WL 605734 (D. Del. Jan. 4. 2022) (Andrews, J.) Drug Product and Patent(s)-in-Suit: Vascepa®...
United States Hikma Pharms United States Inc Why The Court Denied Health Net Motion Robins Kaplan Health Net
Source: jdsupra.com
District Court Of Delaware Rules For Generic Pharma's Use Of Skinny Label, But Permits Induced Infringement Suit To Proceed Against Insurer - Food, Drugs, Healthcare, Life Sciences
Hikma received FDA's approval to sell a generic version for the SH indication only and carved out the patented use.
Source: mondaq.com
Two Pharma And Biotech Cases To Watch In 2022 - Intellectual Property
As we enter the second month of 2022, the old saying, "If at first you don't succeed, try, try again" and the famous line, "I'm not dead," from Monty Python and the Holy Grail, come to mind to describe two issues...
Source: mondaq.com
Just Skinny Enough: District Court Dismisses Inducement Claims Against Generic "Skinny Label" | Rothwell, Figg, Ernst & Manbeck, P.C.
On January 4, 2022, the District Court for the District of Delaware granted Hikma Pharmaceuticals USA Inc.’s (“Hikma”) motion to dismiss Amarin Pharma Inc.’s (“Amarin”) infringement...
Source: jdsupra.com
Method-of-Treatment Patents Increasing Value Risk
Patents on methods-of-treatment using pharmaceuticals are being asserted in broad ways against a variety of parties, with potential liabilities of...
Source: pharmaceuticalonline.com
GSK v. Teva and Induced Infringement by AB-Rated Generics: Where Are We Now? | King & Spalding
The Federal Circuit’s October 2020 split decision in GSK v. Teva[i] made waves throughout the pharmaceutical industry and among Hatch-Waxman litigators. In the broadest reading, some see the majority opinion as rendering any manufacturer of a marketed “AB‑rated” generic drug liable for induced infringement of patents covering any of the brand products’ FDA‑approved indications – even where the generic’s labeling “carved out” such an indication to escape infringement under...
Source: jdsupra.com